Skip to main content

2020

Clinical trials

Pharming announces the publication of data from a compassionate use program of RUCONEST® in COVID-19 patients in a peer-reviewed journal

Pharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use program of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.

Read more
Clinical trials

Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.

Read more
Operational updates

Pharming Group announces the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors

Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.

Read more
Operational updates

Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with RUCONEST®

Pharming Group N.V. announces that it has received formal European Commission approval to treat acute hereditary angioedema (HAE) attacks in children with RUCONEST®. Following the positive opinion and recommendation from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the extension of the indication for RUCONEST® received on 26 March 2020.

Read more

Filters

  • Cookies: This website uses cookies Check the cookies page for more information Accept Decline